Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: J Mol Med (Berl). 2018 Oct 23;96(12):1375–1385. doi: 10.1007/s00109-018-1708-8

Table 1.

LOTT Pharmacogenomics Study subjects

Characteristics Genetic data
(n=331)		 Expression data
(n=51)
Measured time points At screening At screening 12-month Follow-up
Randomized to oxygen vs. control 168/163 14/16 11/10
Desaturation*
 Resting only
 Exercise only
 Resting and exercise
48
164
119
6
17
7
4
11
6
Age, years 70.1±6.82 71.8±8.05 71.1±5.75
Sex Male: 194
Female: 137		 Male: 16
Female: 14		 Male: 14
Female: 7
BMI, kg/m^2 28.2±6.14 27.7±5.77 30.3±6.03
Race White: 290
Black: 41		 White: 20
Black: 10		 White: 13
Black: 7
Other: 1
GOLD Spirometry Grade 0: 5
1: 18
2: 115
3: 147
4: 45
NA: 1		 0: 1
1: 3
2: 8
3: 16
4: 2		 1: 3
2: 5
3: 9
4: 3
Pack-years of smoking 59.3±32.3 56.9±46.51 68.8±55.6
Resting oxygen saturation (SpO2) 93.7±2.08 94.3±2.07 93.6±l.94
6 minute walk distance, feet 1060.7±326.96 951.4±271.66 904.1±3 16.44
Post Bronchodilator FEV1 percent predicted 48.2±l7.38 53.6±23.13 56.4±26.29

Plus-minus values represent means ± SD and categorical values represent number of subjects.

BMI=body mass index; GOLD= Global Initiative for Obstructive Lung Disease; FEV1= forced expiratory volume in 1 second

*

Moderate resting desaturation defined as SpO2 89-93%. Moderate exercise-induced desaturation defined as SpO2 ≥80% for >5 minutes and <90% for ≥10 seconds during 6-minute walk test [6].